Jilin Yatai Pharmaceutical Co., LTD. Was founded in 1999,It is a joint venture between Jilin Yatai Group and Dalian Tianfu Technology,Engaged in modern Chinese medicine research and development, production, sales as one of the high-tech enterprises.Total assets of 538 million yuan.With annual sales of over 300 million yuan, it is an independent innovative high-tech enterprise engaged in the research, development, production and sales of modern Traditional Chinese medicine,For "Jilin Province high-tech enterprise", "Jilin Province small giant enterprise".Company's main production, sales, with independent intellectual property rights of national class I Chinese medicine monomer anti-cancer drugs--Ginseng saponin Rg3 and its preparations "ShenYi capsule".Shenyi capsule is China's first oral targeted anti-tumor drug after artemisinin,The main ingredients of ginseng saponin Rg3 content in ginseng at three over one hundred thousand,Industrial production technology has become a world problem,Our company has realized the industrial production of 95% Rg3 for the first time,So that Rg3 capsules participate in the creation of a leading level of technology.In 2014, Shenyi Capsule, a class I Chinese medicinal monomer, won the second prize of National Scientific and Technological Invention in 2013.In 2017, it was included in the national medical insurance directory as one of the first negotiated varieties.In 2016, the enterprise invested more than 100 million yuan in the class I monomer Traditional Chinese medicine forsythiin project,CFDA approved it for phase I-III clinical study.
Enterprise plant covers an area of 41846 square meters,It can produce tablets, capsules, granules and other dosage forms, and has passed the national GMP certification.Existing staff 300 people, after 18 years has created a high-quality, professional team.Adhering to the tenet of innovation, profit and wealth creation, the staff will fully open up the new era of Yatai Pharmaceuticals and make greater contributions to the country and society.
Jilin Yatai Pharmaceutical Co., LTD. Was founded in 1999,It is a joint venture between Jilin Yatai Group and Dalian Tianfu Technology,Engaged in modern Chinese medicine research and development, production, sales as one of the high-tech enterprises.Total assets of 538 million yuan.With annual sales of over 300 million yuan, it is an independent innovative high-tech enterprise engaged in the research, development, production and sales of modern Traditional Chinese medicine,For "Jilin Province high-tech enterprise", "Jilin Province small giant enterprise".Company's main production, sales, with independent intellectual property rights of national class I Chinese medicine monomer anti-cancer drugs--Ginseng saponin Rg3 and its preparations "ShenYi capsule".Shenyi capsule is China's first oral targeted anti-tumor drug after artemisinin,The main ingredients of ginseng saponin Rg3 content in ginseng at three over one hundred thousand,Industrial production technology has become a world problem,Our company has realized the industrial production of 95% Rg3 for the first time,So that Rg3 capsules participate in the creation of a leading level of technology.In 2014, Shenyi Capsule, a class I Chinese medicinal monomer, won the second prize of National Scientific and Technological Invention in 2013.In 2017, it was included in the national medical insurance directory as one of the first negotiated varieties.In 2016, the enterprise invested more than 100 million yuan in the class I monomer Traditional Chinese medicine forsythiin project,CFDA approved it for phase I-III clinical study.
Enterprise plant covers an area of 41846 square meters,It can produce tablets, capsules, granules and other dosage forms, and has passed the national GMP certification.Existing staff 300 people, after 18 years has created a high-quality, professional team.Adhering to the tenet of innovation, profit and wealth creation, the staff will fully open up the new era of Yatai Pharmaceuticals and make greater contributions to the country and society.